Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC4005-001 · 1 trial · 1 indication
Measured as count of events
| Arm | Type | Description |
|---|---|---|
| NNC4005-0001 | EXPERIMENTAL | Participants will receive a single dose of NNC4005-0001 injected subcutaneously. Trial will include up to 6 ascending single-dose cohorts. |
| Placebo | PLACEBO_COMPARATOR | Participants in each cohort will receive placebo matched to NNC4005-0001 injected subcutaneously. |
| Name | Type | Description |
|---|---|---|
| NNC4005-001 | DRUG | NNC4005-0001 will be given as a single ascending dose via subcutaneous route |
| Placebo | DRUG | Placebo matched to NNC4005-0001 will be given via subcutaneous route |
Inclusion Criteria: * Aged 18-69 years (both inclusive) at the time of signing the informed consent. * Body Mass Index (BMI) of 27.0-40.0 kilogram per square meter (kg/m\^2) (both inclusive) at screening process. * Hepatic fat fraction greater than or equal to (≥) 8% by magnetic resonance imaging p...
NNC4005-001 is an investigational small molecule being developed for fatty liver disease. It is currently in Phase 1 clinical development, studied in adult participants with increased body weight and liver fat. The drug is not yet approved and remains under investigation for this condition.
NNC4005-001 is being developed by Novo Nordisk A/S, a biopharmaceutical company listed on the stock exchange under the ticker NVO. The company is conducting clinical research to evaluate this potential new medicine for fatty liver disease.
NNC4005-001 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The ongoing Phase 1 trial is recruiting participants to study the drug in adults with increased body weight and liver fat.
NNC4005-001 is being studied in one active Phase 1 clinical trial with the identifier NCT07214870. This randomized, double-blind, placebo-controlled study enrolls 60 participants with fatty liver disease in Canada. The trial is currently recruiting adults aged 18 years and older.
Yes, NNC4005-001 is the same drug as NNC4005-0001. The clinical trial NCT07214870 refers to the drug as NNC4005-0001, while the drug name is listed as NNC4005-001. Both names refer to the same investigational medicine for fatty liver disease.